Johnson & Johnson ‘s coronavirus vaccine showed promising results in the United States first phase 1-2a clinical trials, Something that could provide a significant boost to vaccination efforts around the world.
The study, published in the scientific journal New England Journal of Medicine, revealed that the vaccine produced an immune response to neutralizing antibodies in more than 800 people, within two months of inoculation, in a younger population and in people over 65 years of age.
Efforts to distribute the two approved vaccines from Pfizer and Modern have encountered some logistical problems, in part because when using the messenger RNA technology require a extreme cooling, And people should receive two doses to achieve immunity. In the case of Johnson & Johnson, it is a single vaccine, Which would also be more resistant because it is based on DNA technology.
Specifically, the latest results of the trials of phase 1-2a of Johnson & Johnson involve a 805 participants in two groups, One with people aged 18 to 55 years and the other 65 years or older. More than 90% of participants presented a immune response in a month, And all had neutralizing antibody levels on the 57th.
The results also showed a safety profile similar to that of existing vaccines, according to the company instead. the fever was the most common adverse response as well fatigue, headache and body aches.
The good thing is that the results also showed that a second dose of the vaccine more than double the amount of neutralizing antibodies, so it would not be uncommon for this possibility to be contemplated once released. Such a dilemma will be resolved in the results of clinical trials of step 3, which involved a 45 thousand participants and are expected for the end of January.
Recall that Johnson & Johnson briefly paused its trials in October, after a volunteer developed an unexplained neurological disease. A subsequent security investigation determined that the disease was not related to the vaccine.